01 GLP-1-Linked Body Contouring The use of GLP-1 weight-loss medications is creating new demand for aesthetic procedures that address loose skin and changes in body shape after substantial weight loss. The transition toward weight-loss-linked aesthetic care is connecting medication-assisted weight management with body contouring, with ASPS reporting that more than 800,000 aesthetic patients used weight-loss medications in 2024 and 39% of GLP-1 patients surveyed were considering a surgical procedure. This shift is expanding the role of body contouring within the broader weight-management journey in North America. Non-Hyaluronic Acid Injectable Adoption The North America Aesthetic Medicine Market analysis shows that patients and providers are considering non-hyaluronic acid injectables for treatment goals such as collagen stimulation, firmness, and structural support. The transition toward calcium hydroxylapatite and poly-L-lactic acid formulations provides alternatives to traditional HA fillers, with the FDA recognizing both materials as absorbable dermal-filler options. This shift broadens injectable treatment options and supports more personalized approaches to facial rejuvenation.
01 High Training and Certification Requirements for Practitioners and High Cost of Advanced Aesthetic Devices Restrain Market Expansion High training and certification requirements increase the time and cost needed for practitioners to offer advanced aesthetic procedures. These requirements can limit the number of qualified professionals available to clinics, especially for specialized treatments and newer technologies. This workforce constraint can reduce service capacity and slow the adoption of advanced aesthetic procedures.High costs of advanced aesthetic devices increase capital requirements for clinics investing in laser, energy-based, and other specialized treatment technologies.Large equipment investments can be difficult for smaller clinics to manage and may delay technology upgrades or new service launches.This financial barrier can limit technology adoption and constrain the expansion of aesthetic treatment capacity.
01 Aesthetic Treatment Training and Certification Services and Expansion of Aesthetic Treatments for Younger Consumers Offers Growth Opportunities Aesthetic clinics, medical professionals, device manufacturers, and training providers are key beneficiaries, as practitioners need specialized skills for aesthetic procedures and technologies.Training and certification programs create revenue through course fees, workshops, certification programs, and advanced practitioner education. Companies such as Allergan Aesthetics and Merz Aesthetics provide professional education and training programs for aesthetic practitioners.Aesthetic clinics, skincare providers, and treatment manufacturers are key beneficiaries, as younger consumers seek preventive skincare and minimally invasive aesthetic services. This segment creates revenue through tailored treatment packages, skincare products, maintenance programs, and repeat consultations. Companies such as Galderma and Merz Aesthetics offer aesthetic products and solutions that serve a broad range of consumer needs, supporting market growth.
01 Uneven Physician Oversight Across Medspas and Online Promotion of Unapproved Aesthetic Products Hinders Growth Variation in physician supervision makes it difficult for companies to maintain consistent treatment standards across expanding medspa networks. This can increase operational risk and make partnerships, training, and service expansion more complex. Real-life example: A 2025 study found that only 22.52% of Missouri medspas examined had a physician on-site during cosmetic proceduresOnline sellers can market aesthetic products directly to consumers and providers outside established distribution channels. This makes it harder for legitimate companies to control product presentation and compete against unauthorized offerings. Real-life example: In 2025, FDA warned a U.S. seller over unapproved high-concentration lidocaine products promoted for cosmetic procedures through its website and Instagram.
June 2026 AbbVie expanded the North American aesthetic portfolio by introducing new AI-enabled digital tools to support treatment planning and patient consultation across its Allergan Aesthetics business.
April 2026 Galderma launched expanded indications and commercial initiatives for its injectable aesthetics portfolio across North America, strengthening facial aesthetics treatment offerings.
February 2026 Revance Therapeutics expanded commercialization of its DAXXIFY injectable treatment through strategic partnerships with aesthetic practices across the United States.
October 2025 Merz Aesthetics introduced new educational and physician training programs across North America to accelerate adoption of its facial aesthetics portfolio and injection techniques.
August 2025 Candela Corporation expanded its energy-based aesthetic device portfolio with new laser treatment technologies for skin rejuvenation and body contouring across North America.